Companies/US/VRTX

VERTEX PHARMACEUTICALS INCORPORATED

Income flow

Annual
VRTX 10-K Income StatementPeriod 2025-12-31Source 10-K
Trikaftakaftrio$10BAlyftrek$838MManufactured Product Other$820MCasgevy$116MJournavx$60MCollaborativeand Royalty$31MRevenue$12B+9% Y/YGross profit$10B+9% Y/YCost of revenue$2BOperating profit$4B+1892% Y/YOperating expenses$6BNet profit$4B+838% Y/YTax$690MR&D & other$4BSG&A$2B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$12.2B
  • Trikaftakaftrio$10.3B84.7%
  • Alyftrek$838M6.9%
  • Manufactured Product Other$820M6.7%
  • Casgevy$116M0.9%
  • Journavx$60M0.5%
  • Collaborativeand Royalty$31M0.3%
By geography
By geography$16.5B
  • United States$7.5B45.9%
  • Outsidethe United States$4.5B27.1%
  • Europe$3.5B21.0%
  • Other Countries Outsideofthe United Statesand Europe$992M6.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).253.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).252.7M
Stock splits
  1. 2:12000-08-24

Valuation

Trailing PE 29.6 (2025-12-31)PE trend

Fiscal PE4

PeriodEPSClosePE
2025-12-3115.32453.3629.6
2023-12-3113.89406.8929.3
2022-12-3112.82288.7822.5
2021-12-319.01219.624.4

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.